Northern Trust Corp lifted its position in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 10.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,457,848 shares of the biopharmaceutical company's stock after buying an additional 135,826 shares during the quarter. Northern Trust Corp owned about 1.11% of Dynavax Technologies worth $18,617,000 as of its most recent filing with the SEC.
Several other large investors have also made changes to their positions in the company. E Fund Management Co. Ltd. grew its stake in shares of Dynavax Technologies by 4.6% in the 4th quarter. E Fund Management Co. Ltd. now owns 17,627 shares of the biopharmaceutical company's stock valued at $225,000 after buying an additional 771 shares in the last quarter. Summit Investment Advisors Inc. grew its stake in shares of Dynavax Technologies by 7.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 13,782 shares of the biopharmaceutical company's stock valued at $176,000 after buying an additional 904 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Dynavax Technologies by 19.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock valued at $83,000 after buying an additional 1,076 shares in the last quarter. Sanctuary Advisors LLC grew its stake in shares of Dynavax Technologies by 6.3% in the 4th quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company's stock valued at $245,000 after buying an additional 1,109 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of Dynavax Technologies by 96.5% in the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 1,169 shares in the last quarter. Institutional investors own 96.96% of the company's stock.
Dynavax Technologies Stock Performance
Shares of DVAX stock traded up $0.16 during trading hours on Friday, reaching $9.67. 1,573,605 shares of the company's stock were exchanged, compared to its average volume of 2,221,120. Dynavax Technologies Co. has a fifty-two week low of $9.22 and a fifty-two week high of $14.63. The stock has a market capitalization of $1.16 billion, a P/E ratio of 53.72 and a beta of 1.26. The business has a fifty day moving average price of $11.87 and a 200-day moving average price of $12.52. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.
Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The business had revenue of $68.16 million for the quarter, compared to analyst estimates of $70.01 million. Analysts predict that Dynavax Technologies Co. will post 0.32 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on DVAX shares. StockNews.com cut Dynavax Technologies from a "buy" rating to a "hold" rating in a research report on Tuesday, May 6th. The Goldman Sachs Group decreased their target price on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a research report on Thursday, April 17th. William Blair reaffirmed an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. HC Wainwright reaffirmed a "buy" rating and set a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, JMP Securities decreased their target price on Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, Dynavax Technologies currently has an average rating of "Hold" and an average price target of $24.00.
Get Our Latest Analysis on DVAX
Dynavax Technologies Profile
(
Free Report)
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Articles
Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
